Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303
Stopped early · Phase 3
Conditions studied: Polycystic Kidney Disease, Adult
In brief
This is a Phase 3, open-label, roll-over study to demonstrate the continued hepatic and non-hepatic safety and renal efficacy of lixivaptan in participants with ADPKD who previously experienced abnormal liver chemistry test results while treated with tolvaptan, were permanently discontinued from the drug for that reason, and subsequently completed study PA-ADPKD-303, the open-label lead-in study with lixivaptan.
Key facts
- Study ID
- NCT05208866
- Run by
- Palladio Biosciences
- People needed
- 1
- Starts
- 2022-02-10
- Expected to finish
- 2022-07-29
- Last updated by the study team
- 2023-05-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Male or female participants with ADPKD who completed study PA-ADPKD-303
- Continued control of hypertension without the use of a diuretic
- Continued adherence to prohibitions on concomitant medications stated in the study PA-ADPKD-303 protocol
- Willing to practice acceptable methods of birth control (both males who have partners of child-bearing potential and females of childbearing potential).
- Able to provide informed consent.
You may not qualify if…
- Any contraindication to continued treatment with lixivaptan
- Clinically significant incontinence, overactive bladder, or urinary retention (e.g., benign prostatic hyperplasia)
- New York Heart Association Functional Class 3 or 4 heart failure or other significant cardiac or electrocardiogram (ECG) findings that could pose a safety risk to the participant
- Hypovolemia on physical examination at Screening
- The following laboratory results based on serum drawn at Visit 24 of PA-ADPKD-303:
- Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) values >1.5 × ULN
- Total bilirubin values >1.5 × ULN
- eGFR <20 mL/min/1.73 m\^2 based on laboratory results from Visit 26 of PA-ADPKD-303
- A finding at Screening that precludes safe participation in the study or participants who are likely to be non-compliant with study procedures in the opinion of the Investigator or medical monitor
Where it is running
- Northeast Clinical Research Center, LLC — Bethlehem, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.